Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation

dc.creatorSzarewski, A
dc.creatorSkinner, SR
dc.creatorGarland, SM
dc.creatorRomanowski, B
dc.creatorSchwarz, TF
dc.creatorApter, D
dc.creatorChow, SN
dc.creatorPaavonen, J
dc.creatorDel Rosario-Raymundo, MR
dc.creatorTeixeira, JC
dc.creatorDe Carvalho, NS
dc.creatorCastro-Sanchez, M
dc.creatorCastellsague, X
dc.creatorPoppe, WAJ
dc.creatorDe Sutter, P
dc.creatorHuh, W
dc.creatorChatterjee, A
dc.creatorTjalma, WA
dc.creatorAckerman, RT
dc.creatorMartens, M
dc.creatorPapp, KA
dc.creatorBajo-Arenas, J
dc.creatorHarper, DM
dc.creatorTorne, A
dc.creatorDavid, MP
dc.creatorStruyf, F
dc.creatorLehtinen, M
dc.creatorDubin, G
dc.date2013
dc.date37196
dc.date2014-08-01T18:30:26Z
dc.date2015-11-26T17:08:26Z
dc.date2014-08-01T18:30:26Z
dc.date2015-11-26T17:08:26Z
dc.date.accessioned2018-03-28T23:57:05Z
dc.date.available2018-03-28T23:57:05Z
dc.identifierJournal Of Infectious Diseases. Oxford Univ Press Inc, v. 208, n. 9, n. 1391, n. 1396, 2013.
dc.identifier0022-1899
dc.identifier1537-6613
dc.identifierWOS:000326377500007
dc.identifier10.1093/infdis/jit360
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/79924
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/79924
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1280367
dc.descriptionBackground. Public Health England has reported a decrease of up to 20.8% in new diagnoses of external genital warts (GWs) among women aged <19 years since the national vaccination program with the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine began in 2008. A post hoc analysis of the phase III PATRICIA (PApilloma TRIal against Cancer In young Adults) trial (NCT00122681) was performed to ascertain whether protection against low-risk HPV types was apparent. Methods. Vaccine efficacy (VE) at 48 months was assessed against 6-month persistent infection (6MPI) with low-risk HPV types in the total vaccinated cohort (TVC) and in the TVC naive (for 25 HPV types tested) populations. Results. In the TVC naive cohort, VE against 6MPI (95% confidence interval) was 34.5% (11.3 to 51.8) for HPV6/11, 34.9% (9.1 to 53.7) for HPV-6, 30.3% (-45.0 to 67.5) for HPV-11, and 49.5% (21.0 to 68.3) for HPV-74. Conclusions. The HPV-16/18 AS04-adjuvanted vaccine appears to have moderate efficacy against persistent infections with a number of low-risk HPV types (HPV-6/11/74), which are responsible for the majority of external GWs, and recently, antibody and cell-mediated immune response to HPV-6/11 have been observed. These findings may help to explain the decrease in external GW diagnoses seen in England.
dc.description208
dc.description9
dc.description1391
dc.description1396
dc.descriptionGlaxoSmithKline group of companies [NCT00122681]
dc.descriptionGlaxoSmithKline group of companies [NCT00122681]
dc.languageen
dc.publisherOxford Univ Press Inc
dc.publisherCary
dc.publisherEUA
dc.relationJournal Of Infectious Diseases
dc.relationJ. Infect. Dis.
dc.rightsfechado
dc.rightshttp://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html
dc.sourceWeb of Science
dc.subjecthuman papillomavirus
dc.subjectHPV
dc.subjectHPV vaccine
dc.subjectgenital warts
dc.subjectPapillomavirus Genotype Distribution
dc.subjectOf-study Analysis
dc.subjectAged 18-45 Years
dc.subjectHpv-6/11/16/18 Vaccine
dc.subject(hpv)-16/18 Vaccine
dc.subjectGenital Warts
dc.subjectImmunogenicity
dc.subjectSafety
dc.titleEfficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución